Full-Time
Quantitative Associate Programme 2026
Systematic Investment
Posted on 9/4/2025
Marshall Wace
501-1,000 employees
Global provider of alternative investments
Compensation Overview
$150k - $165k/yr
London, UK + 1 more
More locations: New York, NY, USA
In Person
 Quantitative Finance (3) |
|---|
| , , |
- For the Quantitative Associate role, we require applicants to have achieved a PhD or master’s degree as a minimum. We also encourage applications from candidates with 2-3 years of relevant industry experience.
- Strong numeracy: While we are flexible on your degree discipline, we do expect candidates to be highly numerate.
- Create value: Our associates need to think critically about a range of strategic issues impacting our business.
- “Shoot for the moon” ambition: We want people who think differently, love devising strategies and are focussed on optimal outcomes.
- Lead the way: You need to bring innovation at all levels, be tenacious and never settle for the status quo.
- Agile minds: You need to show proven ability to move seamlessly between projects, often working on multiple and diverse tasks at the same time.
- Team player: You must also be able to work effectively in a team, helping the group to deliver efficient and superior solutions.
- You’ll be embedded into one of the Systematic Investment teams where, from day one, you’ll actively contribute to the development of our quantitative strategies.
- You’ll be delivering on the research agenda, in addition to back testing/researching forecasts of asset returns on horizons of hours to years.
- As a member of our Quantitative Associate Programme you will be part of a select cohort receiving on the job training from experienced colleagues who have a matchless record of helping high performing individuals reach their true potential.
Marshall Wace provides alternative investment solutions to clients around the world. It uses a global, integrated team to design and manage a range of investment strategies focused on delivering risk-adjusted returns for institutions and other investors. The firm works to build long-term client relationships based on trust and integrity, and emphasizes continuous improvement and fresh thinking to create proprietary value that benefits clients. Its products are different from traditional funds in their emphasis on alternative strategies and customized, research-driven approaches, aiming to achieve better outcomes through disciplined, differentiated investment methods. The goal is to grow client value by offering thoughtful, proprietary investment strategies that align with clients’ needs and risk tolerances.
Company Size
501-1,000
Company Stage
N/A
Total Funding
$8.8B
Headquarters
London, United Kingdom
Founded
1997
Simplify's Take
What believers are saying
- Ray Therapeutics RTx-015 optogenetic therapy approval unlocks significant exit valuation and portfolio returns.
- Digital assets division captures growing allocator demand for alternative return sources in crypto space.
- Commodity expertise expansion through senior trader hires strengthens systematic trading across new asset classes.
What critics are saying
- RTx-015 late-stage trial failure eliminates primary Ray Therapeutics return driver within 12-24 months.
- Regulatory crackdown on stablecoins and crypto assets impairs new digital division returns by 2026-2027.
- Dodson's failed Philipp Oil venture signals execution risk; oil PM hire may underperform benchmarks.
What makes Marshall Wace unique
- Expanding into digital assets and late-stage fintech investments led by experienced operator Amit Rajpal.
- Recruiting specialized talent including ex-Millennium oil PM Andrew Dodson and ex-Citadel credit analyst.
- Diversifying beyond core long/short equity into blockchain, stablecoins, and commodities trading strategies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Social Events
Company News
Hedge fund Marshall Wace's newest oil PM is an ex-millennium trader. 4 hours ago Moving from Millennium to Marshall Wace - two of the biggest hedge funds in the world - is a pretty normal move as far as the industry goes. Sometimes, however, it takes the better part of a decade and a few side gigs. Andrew Dodson joined Marshall Wace last week as a portfolio manager in its oil team, based in its London office. He joined the firm from DV Trading, a derivatives-focused prop trading firm. He was last employed before that by Millennium as a partner (and portfolio manager) back in 2017. Dodson, whose middle name is Philipp, left Millennium to set up his own hedge fund, Philipp Oil. According to Bloomberg, he was aiming for $500m in assets under management for the launch. However - according to UK register companies house - Philipp Advisors LLP, of which Dodson was a founding member, only ever submitted accounts as a dormant company before being struck off in 2022. He was also the only registered individual with the firm, per the FCA. Confusingly, Dodson was also a member of Sealark LLP, which traded as Philipp Oil for around 18 months in 2018/2019, again per the FCA. Its last full-year accounts, covering 2018, indicate turnover of less than £850k and average profit per member of around £43k. Perhaps Dodson should have stayed at Millennium - the fund has developed a reputation in recent years of fronting some of its star traders with $1bn+ investments to start their own hedge funds. Dodson is not the only new face at Marshall Wace this month. Chet Johal joined the firm this week in London as a portfolio manager from Balyasny, where he spent five years in various analyst and associate roles. And Alexis Wagener joined in New York as a senior credit analyst, having spent two years as a senior associate at Citadel in the city. Marshall Wace declined a request to comment. Dodson did not respond to a request for comment. Have a confidential story, tip, or comment you'd like to share? Contact: +44 7537 182250 (SMS, WhatsApp or voicemail). Telegram: @SarahButcher. Signal: sarahbutcher.22 Click here to fill in our anonymous form, or email [email protected]. Bear with us if you leave a comment at the bottom of this article: comments are moderated intermittently by human beings. Sometimes these humans might be asleep, or away from their desks, so it may take a while for your comment to appear. You must take sole responsibility for comments you post on this site. We will take reasonable steps to weed out anything that we consider to be offensive or inappropriate. The essential daily roundup of news and analysis read by everyone from senior bankers and traders to new recruits. Boost your career. Find thousands of job opportunities by signing up to eFinancialCareers today. Top Articles
(Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to
Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, has announced a $25 million private placement led by Adage Capital Management, with participation from Trails Edge Capital Partners and Marshall Wace. The North Carolina-based company will issue 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock, convertible into common stock subject to stockholder approval. The financing is expected to close on 18 February 2026. Proceeds will fund clinical programmes for gene therapy candidates targeting various retinal disorders, including OPGx-LCA5 and OPGx-BEST1. Combined with its year-end 2025 cash balance of $70 million, the company expects to fund operations into the first half of 2028. Opus Genetics did not use a placement agent for the offering.
RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 -- Opus Genetics, Inc. , a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with...
Comprehensive medical intelligence platform providing access to clinical trials, drug data, patents, scientific literature, and research insights.